CA3071786C - Prevention and/or treatment of neurodegenerative disease - Google Patents

Prevention and/or treatment of neurodegenerative disease Download PDF

Info

Publication number
CA3071786C
CA3071786C CA3071786A CA3071786A CA3071786C CA 3071786 C CA3071786 C CA 3071786C CA 3071786 A CA3071786 A CA 3071786A CA 3071786 A CA3071786 A CA 3071786A CA 3071786 C CA3071786 C CA 3071786C
Authority
CA
Canada
Prior art keywords
compositions
use according
omega
fatty acid
zeaxanthin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3071786A
Other languages
English (en)
French (fr)
Other versions
CA3071786A1 (en
Inventor
Alan Norman Howard
John Nolan
Riona Mulcahy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maravilla LLC
Original Assignee
Maravilla LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maravilla LLC filed Critical Maravilla LLC
Publication of CA3071786A1 publication Critical patent/CA3071786A1/en
Application granted granted Critical
Publication of CA3071786C publication Critical patent/CA3071786C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3071786A 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease Active CA3071786C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1720119.5 2017-12-04
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
CA3071786A1 CA3071786A1 (en) 2019-06-13
CA3071786C true CA3071786C (en) 2023-11-14

Family

ID=60950313

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071786A Active CA3071786C (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Country Status (15)

Country Link
US (1) US10835509B2 (https=)
EP (2) EP4599891A3 (https=)
JP (2) JP7824729B2 (https=)
KR (1) KR20200095452A (https=)
AU (1) AU2018379644B2 (https=)
BR (1) BR112020005132A2 (https=)
CA (1) CA3071786C (https=)
ES (1) ES3047101T3 (https=)
GB (2) GB201720119D0 (https=)
IE (1) IE87241B1 (https=)
MX (1) MX2020002458A (https=)
RU (1) RU2020111305A (https=)
SG (1) SG11202000786RA (https=)
WO (1) WO2019110951A1 (https=)
ZA (1) ZA202000558B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
JPWO2022244727A1 (https=) * 2021-05-17 2022-11-24
JPWO2024143060A1 (https=) * 2022-12-26 2024-07-04

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
EP2219478B1 (en) * 2007-12-17 2017-05-10 Newtricious B.V. Method of producing egg yolk based functional food product and products obtainable thereby
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
EP3372280B1 (en) * 2011-07-07 2020-09-16 Howard Foundation Holdings Limited Improvements in or relating to visual performance
CN104619313A (zh) * 2012-07-19 2015-05-13 以瓦伦萨国际营业的美国营养品有限公司 磷虾油和反应的虾青素组合物以及相关方法
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
HK1211836A1 (en) * 2013-03-28 2016-06-03 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
JP6375296B2 (ja) * 2013-07-10 2018-08-15 ライオン株式会社 脳機能改善用内服組成物、脳内アミロイドβ蓄積抑制用内服組成物、脳機能改善用食品組成物及び脳内アミロイドβ蓄積抑制用食品組成物
WO2017144443A1 (en) * 2016-02-22 2017-08-31 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases.

Also Published As

Publication number Publication date
MX2020002458A (es) 2020-07-20
BR112020005132A2 (pt) 2020-09-15
ES3047101T3 (en) 2025-12-03
SG11202000786RA (en) 2020-06-29
GB201720119D0 (en) 2018-01-17
JP2026016698A (ja) 2026-02-03
IE87241B1 (en) 2021-07-07
NZ761512A (en) 2024-01-26
AU2018379644A1 (en) 2020-03-19
GB201807590D0 (en) 2018-06-27
US20190167624A1 (en) 2019-06-06
KR20200095452A (ko) 2020-08-10
EP3644979B1 (en) 2025-08-06
ZA202000558B (en) 2021-10-27
JP2021505527A (ja) 2021-02-18
WO2019110951A1 (en) 2019-06-13
EP4599891A2 (en) 2025-08-13
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
AU2018379644B2 (en) 2024-02-08
CA3071786A1 (en) 2019-06-13
RU2020111305A (ru) 2022-01-10
US10835509B2 (en) 2020-11-17
EP3644979A1 (en) 2020-05-06
GB2568986B (en) 2019-12-18
JP7824729B2 (ja) 2026-03-05
EP4599891A3 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
Welty Omega-3 fatty acids and cognitive function
Van Dael Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations
Stringham et al. Lutein across the lifespan: From childhood cognitive performance to the aging eye and brain
Traber et al. Vitamin E revisited: do new data validate benefits for chronic disease prevention?
Rautiainen et al. Dietary supplements and disease prevention—a global overview
Berson et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A
Otaegui-Arrazola et al. Diet, cognition, and Alzheimer’s disease: food for thought
JP2026016698A (ja) 神経変性疾患の予防及び／又は治療
Arnold et al. Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: A randomized trial
Milaneschi et al. Nutritional determinants of mobility
Sanders Protective effects of dietary PUFA against chronic disease: evidence from epidemiological studies and intervention trials
Demirel et al. The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study
Yoshizako et al. Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects
Bowen et al. Carotenoids in human nutrition
US20200197349A1 (en) Cognitive function
Włodarek The possibility of use of the ketogenic diet and medium chain triglycerides supplementation in the support therapy of Alzheimer disease
HK40130790A (en) Prevention and/or treatment of neurodegenerative disease
Partinen et al. Nutrition, sleep and sleep disorders–relations of some food constituents and sleep
US20190307715A1 (en) Prevention and/or treatment of neurodegenerative disease
Bone et al. Efficacy of diacetate esters of macular carotenoids: effect of supplementation on macular pigment
US20150272918A1 (en) Method for alleviating fear memory
Takeda et al. Effects of mayonnaise on postprandial serum lutein/zeaxanthin and β-carotene concentrations in humans
Summerton Omega-3s: what they can do for you: whether you agree or disagree with the claims, make sure you know the science
Petyaev et al. Pharmacokinetics and oxidation parameters in volunteers supplemented with microencapsulated docosahexaenoic acid
Ulbricht An evidence-based systematic review of lutein by the Natural Standard Research Collaboration

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210728

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502